RSV Vaccination Prevents Associated Hospitalization, Emergency Encounters
By Elana Gotkine HealthDay Reporter
THURSDAY, Nov. 7, 2024 -- For adults aged 60 years or older, respiratory syncytial virus (RSV) vaccination is effective for preventing associated hospitalizations and emergency department encounters, according to a study published online Oct. 19 in The Lancet.
Amanda B. Payne, Ph.D., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues assessed the effectiveness of RSV vaccines against RSV-associated hospitalizations and emergency department encounters among adults aged 60 years or older who underwent virus testing from Oct. 1, 2023, to March 31, 2024.
The researchers found that vaccine effectiveness was 80 and 81 percent against RSV-associated hospitalizations and against RSV-associated critical illness among 28,271 hospitalizations for RSV-like illness among adults aged 60 years or older without immunocompromising conditions. Vaccine effectiveness was 73 percent against associated hospitalizations among 8,435 hospitalizations in adults with immunocompromising conditions. Vaccine effectiveness was 77 percent against RSV-associated emergency department encounters among 36,521 emergency department encounters for RSV-like illness among adults aged 60 years or older without an immunocompromising condition.
"These findings provide additional context regarding the benefit of respiratory syncytial virus vaccination among adults aged at least 60 years," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
Older Adults Have Low Knowledge of RSV Disease and Vaccine Eligibility
MONDAY, April 7, 2025 -- Knowledge of respiratory syncytial virus (RSV) disease and RSV vaccine eligibility is low among hospitalized older adults, according to a study published...
COVID-19 Linked to More Severe Outcomes Than Flu, RSV in 2022-2023 Season
THURSDAY, Jan. 30, 2025 -- COVID-19 was associated with more severe disease outcomes than influenza or respiratory syncytial virus (RSV) during the 2022 to 2023 season, according...
Eight in 10 Infants Received RSV Protection in the 2023 to 2024 Season
WEDNESDAY, Jan. 8, 2025 -- Eight in 10 infants received respiratory syncytial virus (RSV) protection during the 2023 to 2024 season, according to a research letter published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.